KalVista Pharmaceuticals, Inc. Insider Trading for February 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in KalVista Pharmaceuticals, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in KalVista Pharmaceuticals, Inc. for February 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25 2021 | KALV | KalVista Pharmaceu ... | Yea Christopher | Chief Development O ... | Sell | S | 31.87 | 500 | 15,933 | 47,969 | 48.5 K to 48 K (-1.03 %) |
| Feb 25 2021 | KALV | KalVista Pharmaceu ... | Yea Christopher | Chief Development O ... | Sell | S | 32.94 | 3,311 | 109,059 | 48,469 | 51.8 K to 48.5 K (-6.39 %) |
| Feb 25 2021 | KALV | KalVista Pharmaceu ... | Yea Christopher | Chief Development O ... | Sell | S | 33.74 | 10,389 | 350,572 | 51,780 | 62.2 K to 51.8 K (-16.71 %) |
| Feb 25 2021 | KALV | KalVista Pharmaceu ... | Yea Christopher | Chief Development O ... | Sell | S | 35.39 | 800 | 28,314 | 62,169 | 63 K to 62.2 K (-1.27 %) |
| Feb 25 2021 | KALV | KalVista Pharmaceu ... | Palleiko Benjamin L | CFO, CBO & Secretar ... | Option Exercise | M | 6.74 | 29,642 | 199,787 | 29,611 | |
| Feb 25 2021 | KALV | KalVista Pharmaceu ... | Palleiko Benjamin L | CFO, CBO & Secretar ... | Sell | S | 31.77 | 1,256 | 39,908 | 65,000 | 66.3 K to 65 K (-1.90 %) |
| Feb 25 2021 | KALV | KalVista Pharmaceu ... | Palleiko Benjamin L | CFO, CBO & Secretar ... | Sell | S | 33.06 | 5,293 | 174,975 | 66,256 | 71.5 K to 66.3 K (-7.40 %) |
| Feb 25 2021 | KALV | KalVista Pharmaceu ... | Palleiko Benjamin L | CFO, CBO & Secretar ... | Sell | S | 33.73 | 22,093 | 745,274 | 71,549 | 93.6 K to 71.5 K (-23.59 %) |
| Feb 25 2021 | KALV | KalVista Pharmaceu ... | Palleiko Benjamin L | CFO, CBO & Secretar ... | Sell | S | 35.40 | 1,000 | 35,404 | 93,642 | 94.6 K to 93.6 K (-1.06 %) |
| Feb 25 2021 | KALV | KalVista Pharmaceu ... | Palleiko Benjamin L | CFO, CBO & Secretar ... | Buy | M | 6.74 | 29,642 | 199,787 | 94,642 | 65 K to 94.6 K (+45.60 %) |
| Feb 25 2021 | KALV | KalVista Pharmaceu ... | Feener Edward P. | Chief Scientific Of ... | Sell | S | 31.73 | 800 | 25,384 | 54,234 | 55 K to 54.2 K (-1.45 %) |
| Feb 25 2021 | KALV | KalVista Pharmaceu ... | Feener Edward P. | Chief Scientific Of ... | Sell | S | 32.97 | 5,471 | 180,400 | 55,034 | 60.5 K to 55 K (-9.04 %) |
| Feb 25 2021 | KALV | KalVista Pharmaceu ... | Feener Edward P. | Chief Scientific Of ... | Sell | S | 33.72 | 23,441 | 790,534 | 60,505 | 83.9 K to 60.5 K (-27.92 %) |
| Feb 25 2021 | KALV | KalVista Pharmaceu ... | Feener Edward P. | Chief Scientific Of ... | Sell | S | 35.19 | 1,288 | 45,325 | 83,946 | 85.2 K to 83.9 K (-1.51 %) |
| Feb 25 2021 | KALV | KalVista Pharmaceu ... | Crockett Thomas Andrew | CEO | Sell | S | 31.87 | 707 | 22,531 | 169,420 | 170.1 K to 169.4 K (-0.42 %) |
| Feb 25 2021 | KALV | KalVista Pharmaceu ... | Crockett Thomas Andrew | CEO | Sell | S | 32.94 | 1,575 | 51,877 | 170,127 | 171.7 K to 170.1 K (-0.92 %) |
| Feb 25 2021 | KALV | KalVista Pharmaceu ... | Crockett Thomas Andrew | CEO | Sell | S | 33.73 | 7,218 | 243,430 | 171,702 | 178.9 K to 171.7 K (-4.03 %) |
| Feb 25 2021 | KALV | KalVista Pharmaceu ... | Crockett Thomas Andrew | CEO | Sell | S | 35.40 | 500 | 17,700 | 178,920 | 179.4 K to 178.9 K (-0.28 %) |
| Feb 08 2021 | KALV | KalVista Pharmaceu ... | Smith Michael David | Senior VP, Developm ... | Option Exercise | A | 10.20 | 16,500 | 168,300 | 16,500 | |
| Feb 08 2021 | KALV | KalVista Pharmaceu ... | Palleiko Benjamin L | CFO, CBO & Secretar ... | Option Exercise | A | 10.20 | 20,000 | 204,000 | 20,000 | |
| Feb 08 2021 | KALV | KalVista Pharmaceu ... | Palleiko Benjamin L | CFO, CBO & Secretar ... | Option Exercise | A | 24.23 | 37,500 | 908,625 | 37,500 | |
| Feb 08 2021 | KALV | KalVista Pharmaceu ... | Palleiko Benjamin L | CFO, CBO & Secretar ... | Grant | A | 0.00 | 32,500 | 0 | 65,000 | 32.5 K to 65 K (+100.00 %) |
| Feb 08 2021 | KALV | KalVista Pharmaceu ... | Maetzel Andreas | Senior Vice Preside ... | Option Exercise | A | 10.20 | 10,000 | 102,000 | 10,000 | |
| Feb 08 2021 | KALV | KalVista Pharmaceu ... | Maetzel Andreas | Senior Vice Preside ... | Option Exercise | A | 24.23 | 10,000 | 242,300 | 10,000 | |
| Feb 08 2021 | KALV | KalVista Pharmaceu ... | Feener Edward P. | Chief Scientific Of ... | Option Exercise | A | 10.20 | 20,000 | 204,000 | 20,000 | |
| Feb 08 2021 | KALV | KalVista Pharmaceu ... | Feener Edward P. | Chief Scientific Of ... | Option Exercise | A | 24.23 | 22,500 | 545,175 | 22,500 | |
| Feb 08 2021 | KALV | KalVista Pharmaceu ... | Feener Edward P. | Chief Scientific Of ... | Grant | A | 0.00 | 12,500 | 0 | 85,234 | 72.7 K to 85.2 K (+17.19 %) |
| Feb 08 2021 | KALV | KalVista Pharmaceu ... | Crockett Thomas Andrew | CEO | Option Exercise | A | 10.20 | 40,000 | 408,000 | 40,000 | |
| Feb 08 2021 | KALV | KalVista Pharmaceu ... | Crockett Thomas Andrew | CEO | Option Exercise | A | 24.23 | 75,000 | 1,817,250 | 75,000 | |
| Feb 08 2021 | KALV | KalVista Pharmaceu ... | Yea Christopher | Chief Development O ... | Option Exercise | A | 10.20 | 20,000 | 204,000 | 20,000 | |
| Feb 08 2021 | KALV | KalVista Pharmaceu ... | Yea Christopher | Chief Development O ... | Option Exercise | A | 24.23 | 31,000 | 751,130 | 31,000 |